PMCB
PharmaCyte Biotech Inc
NASDAQ: PMCB · HEALTHCARE · BIOTECHNOLOGY
$0.33
-2.45% today
Updated 2026-10-28
Market cap
$3.65M
P/E ratio
—
P/S ratio
12,904.41x
EPS (TTM)
$-2.31
Dividend yield
—
52W range
$0 – $2
Volume
0.2M
WallStSmart proprietary scores
26
out of 100
Grade: F
Strong Sell
Investment rating
4.3
Growth
C5.3
Quality
C+3.0
Profitability
D5.0
Valuation
C+2/9
Piotroski F-Score
Weak
-0.8
Altman Z-Score
Distress
—
Industry rank
—
View all highly rated stocks (75+) →270 stocks currently score above 75
Price targets
Analyst target
—
—
12-Month target
—
—
Intrinsic (DCF)
—
Margin of safety
—
Price chart
Stock snapshot
Strengths
Insufficient data
Risks
- Piotroski 2/9 — weak financial health
- Altman Z -0.78 — distress zone
- Thin margins at 0.00%
- Negative free cash flow $-780894.00
Key financials
Revenue Net Income Free Cash Flow
| Metric | 2023 | 2024 | 2025 | 2026 | TTM |
|---|---|---|---|---|---|
| Revenue | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
| Net income | $-4.32M | $333763.00 | $30.66M | $-19.42M | $-5.08M |
| EPS | — | — | — | — | $-2.31 |
| Free cash flow | $-3.79M | $-2.15M | $-2.98M | $-5.15M | $-780894.00 |
| Profit margin | — | — | — | — | — |
Peer comparison
Smart narrative
PharmaCyte Biotech Inc trades at $0.33. Our Smart Value Score of 26/100 indicates the stock is weak. The company scores 2/9 on the Piotroski F-Score. With an Altman Z-Score of -0.78, it sits in the distress.
Frequently asked questions
What is PharmaCyte Biotech Inc's stock price?
PharmaCyte Biotech Inc (PMCB) trades at $0.33, on a P/S of 12,904.4x. Those multiples show what the market is paying for each dollar of earnings and sales, which is the real starting point for judging whether the price is reasonable.
Is PharmaCyte Biotech Inc overvalued?
PharmaCyte Biotech Inc carries a Smart Value Score of 26/100 (Grade F), which we rate Strong Sell. That score blends growth, quality, and valuation into one read.
Altman Z-Score?
PharmaCyte Biotech Inc's Altman Z-Score is -0.78, which places it in the distress. The Altman Z-Score gauges bankruptcy risk from profitability, leverage, and asset efficiency, and a higher reading points to lower financial distress risk.
Company info
SectorHEALTHCARE
IndustryBIOTECHNOLOGY
CountryUSA
ExchangeNASDAQ
CurrencyUSD
Quick metrics
P/S ratio12,904.41x
ROE-8.42%
Beta0.68
50D MA$0.46
200D MA$0.67
Shares out0.01B
Float0.01B
Short ratio—
Avg volume0.2M
Performance
1 week—
1 month—
3 months—
YTD—
1 year—
3 years—
5 years—